Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD5 | Q86SK9 | 10/20 | 0.58 |
| ▸ | SCD | O00767 | 10/20 | 0.58 |
| ▸ | TRPC3 | Q13507 | 1/20 | 0.56 |
| ▸ | TRPC6 | Q9Y210 | 1/20 | 0.56 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.55 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.55 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.52 |
| ▸ | CCNC | P24863 | 1/20 | 0.50 |
| ▸ | CDK8 | P49336 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31453135 | 0.90 | CCNC (0.51) | SCD5SCDTRPC3TRPC6HSP90AA1 | |
| SCHEMBL31453265 | 0.88 | SCD5 (0.56) | SCD5SCDTRPC3TRPC6HSP90AA1 | |
| SCHEMBL166963 | 0.78 | RIPK1 (0.54) | SCD5SCDTRPC3TRPC6HSP90AA1 | |
| SCHEMBL31431907 | 0.77 | SCD5 (0.59) | SCD5SCDTRPC3TRPC6HSP90AA1 | |
| SCHEMBL31453180 | 0.77 | CCNC (0.50) | SCD5SCDCCNCCDK8 | |
| SCHEMBL256556 | 0.77 | RIPK1 (0.53) | SCD5SCDTRPC3TRPC6HSP90AA1 | |
| SCHEMBL18135148 | 0.76 | SCD5 (0.67) | SCD5SCD | |
| SCHEMBL168416 | 0.74 | RIPK1 (0.53) | SCD5SCDHSP90AA1HSP90AB1RIPK1 | |
| SCHEMBL21535920 | 0.73 | SCD (1.00) | SCD5SCD | |
| SCHEMBL21535917 | 0.73 | SCD (1.00) | SCD5SCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025051157-A1 | PYRIDINE-2(1H)-KETONE PRMT5-MTA INHIBITOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | 赛诺哈勃药业（成都）有限公司 | 2025-03-13 | — | — | WO | disclosed |